The increased capacity depends on Moderna getting approval for a half dose of an updated version of the mRNA-1273 vaccine – targeting new variants of SARS-CoV-2 – that could be used as a booster shot and for immunising children.
The extra line at Lonza’s Geleen site in the Netherlands will allow Moderna to supply the EU with 600 million doses – assuming it gets regulatory approval for using a 50 mcg dose rather than the current 100 mcg. It should be up and running before the end of the year, said the company.
